Xenta

Founded in 2022, Xenta, with "light-induced chemiluminescence" as its core technology, has built a diversified technical system covering the dry light-induced chemiluminescence POCT platform, chip-based ultra-multiplex molecular POCT platform, and immunochromatographic POCT platform. The company's product pipeline covers multiple testing scenarios including cardiovascular, inflammation, hormones, tumors, thyroid function, diabetes, reproductive health, and infectious pathogens, addressing both grassroots rapid testing and high-end precision diagnostics market demands.